The aim of the invention is to provide an application of directional killing of cisplatin-resistant human bladder cancer cell line T24/DDP with CD3 *B7H3 bispecific antibody. Specifically, the application of CD3 *B7H3 bispecific antibody can enhance the killing effect of activated T cells (ATC) on the cisplatin-resistant bladder cancer cell line T24/DDP, and provide a new target therapy for the drug resistance of bladder cancer. Immunotherapy target. The present invention has proved that B7H3 is highly expressed in T24/DDP cisplatin-resistant bladder cancer cells; compared with untouched CD3*B7H3 bispecific antibody ATC, ATC combined with CD3*B7H3 bispecific antibody has enhanced directional killing ability of T24/DDP cisplatin-resistant bladder cancer cells, and has significant cytotoxicity to T24/DDP-resistant bladder cancer cells. When ATC combined with CD3 *B7H3 bispecific antibody was co-cultured with tumor cells at a target-to-effect ratio of 10:1, the killing effect increased significantly. Meanwhile, the levels of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) secreted by ATC combined with CD3 *B7H3 bispecific antibody increased.
【技术实现步骤摘要】
关于CD3×B7H3双特异性抗体定向杀伤耐顺铂膀胱癌细胞T24/DDP的应用
本专利技术的目的在于提供一种偶联CD3×B7H3双特异性抗体定向杀伤耐顺铂膀胱癌细胞T24/DDP的应用，具体为偶联CD3×B7H3双特异性抗体可增强活化T细胞（ATC）对T24/DDP耐顺铂膀胱癌细胞的杀伤作用，为膀胱癌耐药的靶向治疗提供新的免疫治疗靶点。
技术介绍
膀胱癌是男性中第四常见的癌症，女性中第11常见的癌症。2017年在美国估计有79030例新发膀胱癌病例和19870例死亡病例，其中男性发病率和死亡率高于女性4倍。最初，约85%的膀胱癌患者被诊断为浅表性膀胱癌，超过50%的浅表性膀胱癌会复发，并且，仅有46%的三期患者和15%的4期患者可以达到五年生存。因此，膀胱癌患者所面临的形式非常严峻。尽管存在多种治疗方法，比如说手术，放疗，化疗，膀胱癌的术后生存率依旧很不理想。这些治疗方法可以限制肿瘤的发展及生长，但它们无法遏制肿瘤的复发和耐药的产生。因此，发展新的疗法对膀胱癌患者是至关重要的。随着免疫学的研究进展，免疫治疗被公认为二十一世纪肿瘤综合治疗模式中第四种治疗方法。例如，靶...
【技术保护点】
1.偶联CD3×B7H3双特异性抗体定向杀伤人膀胱癌耐药细胞的应用。
【技术特征摘要】
1.偶联CD3×B7H3双特异性抗体定向杀伤人膀胱癌耐药细胞的应用。2.根据权利要求1所述的应用，其特征在于，所述膀胱癌耐药细胞为T24/DDP耐顺铂膀胱癌细胞。3.根据权利要求1所述的应用，其特征在于，偶联CD3×B7H3双特异性抗体的结构如图1。4.根据权利要求3所示的应用，其特征在于，双特...
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。